Letter by Löwe et al Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Vallejo-Vaz et al1 sought to determine the potential long-term benefits of lipid-lowering therapy in the primary prevention of atherosclerotic cardiovascular diseases over 20 years. Their post hoc analysis of 15-year observational follow-up data in WOSCOPS (West of Scotland Coronary Prevention Study), a large randomized controlled trial in Scotland, showed that pravastatin reduced major adverse cardiovascular events in the long term among 2560 apparently healthy men with high low-density lipoprotein cholesterol ≥190 mg/dL at baseline. However, their study did not answer the core question: Will providing statins to people at low risk of atherosclerotic cardiovascular diseases lower their risk even more?
We disagree …